A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here we present a readily applicable protocol to assess the storage stability of extracellular vesicles, a group of naturally occurring nanoparticles produced by cells. The vesicles are loaded with glucuronidase as a model enzyme and stored under different conditions. After storage, their physicochemical parameters and the activity of the encapsulated enzyme are evaluated.

Abstract

Extracellular vesicles (EVs) are promising targets in current research, to be used as drugs, drug-carriers, and biomarkers. For their clinical development, not only their pharmaceutical activity is important but also their production needs to be evaluated. In this context, research focuses on the isolation of EVs, their characterization, and their storage. The present manuscript aims at providing a facile procedure for the assessment of the effect of different storage conditions on EVs, without genetic manipulation or specific functional assays. This makes it possible to quickly get a first impression of the stability of EVs under a given storage condition, and EVs derived from different cell sources can be compared easily. The stability measurement is based on the physicochemical parameters of the EVs (size, particle concentration, and morphology) and the preservation of the activity of their cargo. The latter is assessed by the saponin-mediated encapsulation of the enzyme beta-glucuronidase into the EVs. Glucuronidase acts as a surrogate and allows for an easy quantification via the cleavage of a fluorescent reporter molecule. The present protocol could be a tool for researchers in the search for storage conditions that optimally retain EV properties to advance EV research toward clinical application.

Introduction

EVs are membrane-bound nanoparticles produced by nearly all cell types. For mammalian cells, EVs can be subdivided into two main groups with distinct production pathways1,2. Membrane vesicles, with a size range from roughly 100-1,000 nm, are produced by direct budding from the cell membrane. Exosomes, sized 30-200 nm, are derived from multivesicular bodies formed by inward budding into endosomes that subsequently fuse with the cell membrane to release multiple exosomes at once. The main function of these vesicles is the transport of information between cells3. For this purpose, cargos such as RNA, DNA, and proteins are actively sorted into them. EVs can convey a variety of effects on their targets, with implications for both health and disease state. On one side, they mediate positive effects such as tissue regeneration, antigen presentation, or antibiotic effects, which makes them auspicious targets for their development as therapeutics4,5. On the other side, EVs can promote tumor vascularization6, induce bystander effects in stress responses7, and might play a role in autoimmune diseases8 and inflammatory diseases9. Thus, they might be a key component to a better understanding of many pathological effects. However, the presence of altered EVs in manifold diseases, such as cancer10,11,12 and cardiovascular disorders13, and their easy accessibility in blood and urine makes them ideal biomarkers. Finally, their good biocompatibility14 and their inherent targeting ability make EVs also interesting for drug delivery15. In this manuscript, we describe a protocol for the evaluation of the storage stability of EVs derived from mammalian cells, an important property that is still little investigated.

For the clinical development of EVs, there are still many obstacles to surmount16, including the evaluation of their therapeutic effects, production, purification, and storage17. While -80 °C is widely seen as the gold standard for EV storage18, the required freezers are expensive, and maintaining the required cold chain from the production to the patient can be challenging. Moreover, some reports indicate that storage at -80 °C still not optimally preserves EVs and induces a loss in EV functionality19,20. Other methods, such as freeze-drying21,22 or spray-drying23, have been proposed as potential alternatives to the frozen storage of EVs.

The optimal way of assessing storage stability would be to test the EVs in functional assays or by the evaluation of a specific marker, for instance, their antibacterial activity19. This is possible when the desired effect of the vesicles is known and when one distinct group of EVs is to be studied. If EVs from different cell sources are to be compared (e.g., for drug encapsulation) or if there is no known functional readout, it is no longer possible to assess changes due to storage in a direct manner.

On the other hand, simply evaluating changes in their physicochemical parameters, such as size, particle recovery, and protein concentration, does not always predict changes in EV activity, as has been shown in a recent patent20.

Here, we provide a readily applicable protocol for measuring the storage stability of EVs by assessing their physicochemical parameters combined with the activity of an encapsulated beta-glucuronidase enzyme as a surrogate for the cargo of the EVs. The loading of the enzyme is done by saponin incubation, a mild method established with EVs from different sources21,24,25. Saponin forms transient pores in the EV membrane, which allows enzyme uptake into the vesicle. As enzymes are prone to lose their activity if subjected to unfavorable storage conditions, they are an ideal surrogate for the evaluation of the preservation of functional cargoes of the EVs.

We have demonstrated that the application of this protocol to EVs derived from human mesenchymal stem cells (MSCs), human umbilical vein endothelial cells (HUVECs), and human adenocarcinoma alveolar epithelial cells (A549) indeed result in great differences in storage stability between different cell lines, which should be taken into consideration when choosing the EV source21.

Protocol

1. Cell culture and the production of cell-conditioned medium

  1. Generally, cultivate cells under the individual conditions required for the respective cell line.
  2. Cultivate the cells for 24-72 h in serum-free conditions or in medium containing EV-depleted fetal bovine serum (FBS).
    NOTE: If EV-depleted FBS is used, employ a method proven to efficiently deplete the serum, to prevent contamination with bovine serum-derived EVs26.
  3. Collect the medium from the flasks. Centrifuge at 300 x g for 10 min to pellet the cells. Carefully collect the cell-conditioned medium (CCM), without disturbing the pelleted cells. Preferably, use the CCM directly, or store it overnight at 4 °C.
    NOTE: It is always preferable to use freshly produced CCM. If storage for longer time periods cannot be circumvented, all relevant parameters should be recorded in accordance with MISEV2018 guidelines26, and the potential biases of the results acquired need to be taken into consideration.
  4. Example protocol for HUVECs
    1. Cultivate HUVEC cells for 120 h in EGM-2 medium containing FBS and other supplements.
    2. Cultivate HUVEC cells for 48 h in EBM-2 basal medium free of any additional supplements.
    3. Collect the medium from the flasks and perform the centrifugation step as indicated above (step 1.3). Typically, use 100 mL of medium for one EV-isolation.

2. Ultracentrifugation of CCM

  1. Immediately before ultracentrifugation (UC), centrifuge the CCM for 15 min at 3,000 x g and 4 °C to remove cell debris and large agglomerates.
  2. Carefully transfer the supernatant to the UC tubes. If using a fixed angle rotor, mark the orientation of the tubes in the centrifuge to facilitate the retrieval of the EV pellet after the UC. Centrifuge for 2 h at 120,000 x g, with a k-factor of 259.4.
  3. After UC, carefully discard the supernatant using a serological pipet, to avoid the disturbance of the pelleted EVs.
    NOTE: The pellet might be invisible.
  4. Add 200 µL of 0.2 µm-filtered phosphate-buffered saline (PBS) to the first tube and use PBS and the residual supernatant to resuspend the pellet by pipetting up and down. Transfer the resulting EV suspension to the next tube of the respective sample and use it for the resuspension. Proceed this way to resuspend all EVs of the sample in a final volume of approximately 300-350 µL.
  5. After resuspension, confirm the presence of particles by nanoparticle tracking analysis (NTA). Use the settings optimized for the given EV type, such as the settings below (step 2.5.1).
    NOTE: The papers of Gardiner et al.27 and Vestad et al.28 contain valuable information on how to optimize the parameters for measuring EVs.
    1. To reproduce the results described below, use instruments (e.g., NanoSight LM14) equipped with a green laser. Record three videos of 30 s with a screen gain of 1.0 and a camera level of 13. For analysis, use a screen gain of 1.0 and a detection threshold of 5.
  6. Use the pellet immediately, if possible; otherwise, store it at 4 °C overnight.

3. Glucuronidase encapsulation into EVs

  1. To the resuspended pellet, add beta-glucuronidase (10 mg/mL in PBS) to a final concentration of 1.5 mg/mL and saponin (10 mg/mL in H2O) to a final concentration of 0.1 mg/mL. Mix well by vortexing for 3 s.
  2. Incubate for 10 min at room temperature with intermitted mixing by gently flicking the tube. After incubation, directly purify by size-exclusion chromatography (SEC) (see section 5).
    NOTE: Do not refreeze glucuronidase samples once thawed, to prevent enzyme degradation due to freezing.

4. Liposome production

  1. To prepare liposomes for comparison with EVs, dissolve 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) in a 2:3 molar ration in chloroform to a final concentration of 5 mM. Prepare 1 mL aliquots in high-performance liquid chromatography (HPLC) vials and let them dry overnight to form a lipid film.
    CAUTION: Chloroform is toxic and suspected to be cancerogenic. Take proper precautions when handling it.
  2. Rehydrate the lipid-film with 1 mL of PBS containing 1.5 mg/mL glucuronidase. Heat it to 42 °C and vortex for 1 min. Heat the extruder assembly to 42 °C and extrude the lipid suspension 11x through a 200 nm polycarbonate membrane. Directly purify by SEC (see section 5).

5. Purification by SEC

  1. Prepare the SEC column using the following protocol.
    1. Use only fresh purified water and freshly prepared buffers. Filter all buffers through a 0.2 µm membrane filter and degas them to prevent the formation of air bubbles in the column.
    2. For the preparation of an SEC column, use agarose gel filtration-based matrix (e.g., Sepharose Cl-2b) or another SEC medium suitable to separate EVs and liposomes from protein impurities and excess enzyme. First, remove the 20% EtOH solution the medium is stored in, to prevent air bubble formation in the column. To this end, centrifuge the SEC medium at 3,000 x g for 10 min, remove the EtOH, and replace it with degassed water.
    3. Fill a glass column (with an inner diameter of 10 mm) with the SEC medium to the 15 mL mark.
      NOTE: Volumes will differ for columns with different dimensions. Make sure to let the gel settle completely.
    4. Before a run, equilibrate the column with at least two column volumes of PBS. To store the column, first wash it with one column volume of water, followed by at least two column volumes of 20% EtOH. After storage, wash the column first with one column volume of water before equilibrating with PBS.
    5. Use up to 400 µL of EV or liposome suspension in one separation. Collect fractions of 1 mL. After SEC, either store the purified EVs (see section 7) or subject them to a glucuronidase assay (see section 6).
  2. Confirm the separation of EVs and liposomes from contaminating proteins and free glucuronidase. To this end, correlate the particle concentrations of the collected fractions with the protein concentration and the glucuronidase activity.
    1. Assess the particle concentration by NTA (see 2.5)
    2. Assess the protein content by bicinchoninic acid (BCA) assay or another suitable protein quantification assay. Perform the assay according to the manufacturer’s protocol.
    3. Assess the glucuronidase activity by glucuronidase assay (see section 6).
  3. Optionally, assess the EV morphology by transmission electron microscopy (TEM) and scanning electron microscopy (SEM).
    1. For the preparation of TEM samples, add 10 µL of EV suspension to a TEM grid, incubate for 10 min, and then blot away any excess liquid using a filter paper. Perform the fixation for 10 min with 10 µL of 4% paraformaldehyde and blot away any excess. Wash 3x with water. Stain the vesicles by 20 s incubation with 30 µL of 1% phosphor-tungstic acid hydrate. After blotting away the excess, dry the vesicles overnight. Visualize by TEM.
      CAUTION: Phospho-tungstic acid is highly caustic; thus, protect skin and eyes.
    2. For SEM, fix the previously prepared TEM samples onto carbon disks and sputter them with a 50 nm thick gold layer. Visualize by SEM.

6. Glucuronidase assay

  1. To allow a comparison between different samples and storage conditions by correlating particle number and enzyme activity, first measure the particle concentration of the sample by NTA (see step 2.5).
  2. Prepare a working solution of fluorescein di-β-D-glucuronide by adding 1 µL of the compound (10 mg/mL in H2O) to 199 µL of PBS. Add 25 µL of this solution to 125 µL of purified EVs to get a final concentration of 8.3 µg/mL. Pipet the sample into a black 96-well plate. Measure time point 0 h with a plate reader, using 480 nm as excitation and 516 nm as emission wavelength.
  3. Cover the plate tightly (e.g., with transparent plastic foil used for PCR plates) to minimize evaporation and incubate in the dark for 18 h at 37 °C. Measure the fluorescein production using the plate reader parameters listed in step 6.2.

7. Storage of EVs and liposomes

NOTE: For all storage purposes, it is advisable to use low-binding tubes to reduce EV loss due to adsorption.

  1. Follow the parameters in this section to reproduce the representative results given below. Use samples consisting of 400 µL of EV suspension.
    1. Store at 4 °C or -80 °C or proceed to steps listed below.
    2. Lyophilize the EVs.
      1. Add trehalose (40 mg/mL in H2O) up to a final concentration of 4 mg/mL to the purified EVs. Freeze the samples at -80 °C for at least 1 h.
      2. Lyophilize the samples using the following parameters. For main drying, set the shelf temperature to 15 °C and pressure to 0.180 mbar and leave the samples to dry for 46 h. For final drying, set the shelf temperature to 25 °C and pressure to 0.0035 mbar and leave the samples to dry for 2 h. Store the lyophilized samples at 4 °C.
      3. To rehydrate the samples, add H2O, equal to the amount of EV suspension present in the beginning (typically, 400 µL). Do not use any buffer for rehydration.

8. Analysis after storage

  1. To assess the enzyme activity, first remove the free glucuronidase, which may have leaked from the EVs during storage. Achieve this by an additional step of purification that is carried out either by SEC (see step 5) or asymmetric flow field-flow fractionation (AF4) (see step 8.1.2).
    NOTE: Please be advised that both methods lead to a dilution of the EV sample; thus, use sufficient EV concentrations before storage to avoid moving below the NTA quantification limit. Expect a 1:10 dilution of the particles due to SEC or AF4.
    1. For SEC purification, follow the protocol described above (see section 5).
    2. Perform AF4 purification.
      1. Set up the instrument using a small channel with a 350 µm spacer and a 30 kD molecular weight cut-off cellulose membrane. Place a 0.1 µm pore size filter between the HPLC pump and the AF4 channel. Use freshly prepared 0.1 µm-filtered PBS as the mobile phase to reduce the particle load and noise in the light-scattering detectors.
      2. Detect proteins using a UV detector set to 280 nm. To detect particles, use multiangle light scattering with the laser set to 658 nm.
      3. Use the following run method. Pre-focus for 1 min with a focus flow of 1 mL/min; then, inject 300 µL of the sample at a rate of 0.2 mL/min and keep up the focus flow for 10 min. After the injection, elute the sample at 1 mL/min while applying a cross flow that decreases from 2 mL/min to 0.1 mL/min over the course of 8 min. Elute for another 10 min without cross flow. Collect fractions of 1 mL, starting after 12.5 min and continuing until 27 min.
    3. Perform the glucuronidase assay as described above (see section 6).
  2. To assess the size and concentration, use the NTA as described above (see step 2.5).
  3. Optionally, perform TEM and SEM to assess the morphology of the EVs after storage (see 5.3).

Results

Figure 1 displays the storage characteristics of EVs isolated from HUVECs. EVs were isolated by UC, glucuronidase was encapsulated, and after SEC, the purified EVs were evaluated for their physicochemical properties by NTA. A sample of the vesicles was subsequently subjected to AF4 purification and the glucuronidase activity was measured.

The vesicles were then stored for 7 d at 4 °C or -80 °C and at 4 °C in lyophilized form, in the latter case with the addition...

Discussion

In this manuscript, we present a comprehensive protocol to study the stability of EVs under different storage conditions. With the combination of encapsulated glucuronidase as a functional readout and the evaluation of the physicochemical parameters of the EVs, the protocol allows for a straightforward storage stability evaluation of EVs and the comparison of EVs from different cell lines. SEM and TEM as complementary methods allow an insight into changes of the EVs on the single-particle level. The results presented her...

Disclosures

The authors have nothing to disclose.

Acknowledgements

The NanoMatFutur Junior Research program from the Federal Ministry of Education and Research, Germany (grant number 13XP5029A) supported this work. Maximilian Richter was supported by Studienstiftung des Deutschen Volkes (German Academic Scholarship Foundation) through a Ph.D. fellowship.

Materials

NameCompanyCatalog NumberComments
1,2 dimyristoyl-sn glycero-3-phospho-choline (DMPC)Sigma-AldrichP2663-25MG
1,2-dipalmitoyl-sn-glycero-3-phospho-choline (DPPC)Sigma-AldrichP4329-25MG
225 cm² cell culture flasksCorning431082Used with 25 ml of medium
30 kDa regenerated cellulose membraneWyatt Technology Europe1854
350 µm spacerWyatt Technology Europe
Automated fraction collectorThermo Fisher Scientific
Beta-glucuronidaseSigma-AldrichG7646-100KU
ChloroformFisher scientificC/4966/17
Column ovenHitachi High-Technologies Europe
D-(+)-Trehalose dihydrateSigma-AldrichT9531-10G
DAWN HELEOS II, Multi-angle light scattering detector Wyatt Technology Europe
Durapore Membrane filter, PVDF,  0,1 µm, 47 mmMerckVVLP04700Used for the preparation of buffers for AF4
EBM-2Lonza Verviers, S.p.r.CC-3156Endothelial Cell Growth basal medium, used for the serum free culture of HUVEC cells
Eclipse dualtecWyatt Technology Europe
EGM-2Lonza Verviers, S.p.r.CC-3162Endothelial Cell Growth medium, used for the normal culture of HUVEC cells
ELISA Plate SealersR&D SystemsDY992used for sealing of 96-well plates for the glucuronidase assay
EthanolFisher scientificE/0665DF/17
Extruder Set With Holder/Heating BlockAvanti Polar Lipids610000-1EA
Filter supportAvanti Polar Lipids610014-1EAused for liposome preparation
Fluorescein di-β-D-glucoronideThermo Fisher ScientificF2915
Gibco PBS-tablets+CA10:F36Thermo Fisher Scientific18912014
Hettich Universal 320 RAndreas Hettich GmbH & Co.KGUsed for pelleting cells at 300 g
Hettich Rotina 420 RAndreas Hettich GmbH & Co.KGUsed for pelleting larger debris at 3000 g
HUVEC cellsLonza Verviers, S.p.r.C2517A
Kimble  FlexColumn 1X30CMKimble420401-1030
Lyophilizer ALPHA 2-4 LSCChrist
Microcentrifuge Tubes, PolypropyleneVWR international525-0255the tubes used for all EV-handling, found to be more favorable than comparable products from other suppliers regarding particle recovery
Nanosight LM14 equipped with a green laserMalvern Pananalytical
Nanosight-software version 3.1Malvern Pananalytical
Nucleopore 200 nm track-etch polycarbonate membranesWhatman/GE Healthcare110406used for liposome preparation
PEEK Inline filter holderWyatt Technology Europe
Phosphotungstic acid hydrateSigma-Aldrich79690-25G
Polycarbonate bottles for ultracentrifugationBeckman Coulter355622
QuantiPro BCA Assay KitSigma-AldrichQPBCA-1KT
SaponinSigma-Aldrich47036
Scanning electron microscopy Zeiss EVO HD 15Carl Zeiss AG
Sepharose Cl-2bGE Healthcare17014001
SEM copper grids with carbon filmPlanoS160-4
Small AF4 channelWyatt Technology Europe
Sputter-coater Q150R ESQuorum Technologies
Transmission electron microscopy JEOL JEM 2011Oxford Instruments
Type 45 Ti ultracentrifugation rotorBeckman Coulter339160
Ultimate 3000 Dionex autosamplerThermo Fisher Scientific
Ultimate 3000 Dionex isocratic pumpThermo Fisher Scientific
Ultimate 3000 Dionex online vacuum degasserThermo Fisher Scientific
Ultracentrifuge OptimaTM L-90 KBeckman Coulter
UV detectorThermo Fisher Scientific
Whatman 0.2 µm pore size mixed cellulose filterWhatman/GE Healthcare10401712Used for the filtration of all buffers used with the EVs and in SEC

References

  1. Stremersch, S., De Smedt, S. C., Raemdonck, K. Therapeutic and diagnostic applications of extracellular vesicles. Journal of Controlled Release. 244, 167-183 (2016).
  2. Fuhrmann, G., Herrmann, I. K., Stevens, M. M. Cell-derived vesicles for drug therapy and diagnostics: Opportunities and challenges. Nano Today. 10 (3), 397-409 (2015).
  3. Goes, A., Fuhrmann, G. Biogenic and Biomimetic Carriers as Versatile Transporters To Treat Infections. ACS Infectious Diseases. 4 (6), 881-892 (2018).
  4. György, B., Hung, M. E., Breakefield, X. O., Leonard, J. N. Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions. Annual Review of Pharmacology and Toxicology. 55, 439-464 (2015).
  5. Schulz, E., et al. Biocompatible bacteria-derived vesicles show inherent antimicrobial activity. Journal of Controlled Release. 290, 46-55 (2018).
  6. Feng, Q., et al. A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nature Communications. 8, 14450 (2017).
  7. Bewicke-Copley, F., et al. Extracellular vesicles released following heat stress induce bystander effect in unstressed populations. Journal of Extracellular Vesicles. 6, 1340746 (2017).
  8. Xu, Y., et al. Macrophages transfer antigens to dendritic cells by releasing exosomes containing dead-cell-associated antigens partially through a ceramide-dependent pathway to enhance CD4(+) T-cell responses. Immunology. 149 (2), 157-171 (2016).
  9. Buzas, E. I., György, B., Nagy, G., Falus, A., Gay, S. Emerging role of extracellular vesicles in inflammatory diseases. Nature Reviews Rheumatology. 10, 356 (2014).
  10. Rajappa, P., et al. Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 23 (12), 3109-3119 (2017).
  11. Umezu, T., et al. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124 (25), 3748-3757 (2014).
  12. Costa-Silva, B., et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nature Cell Biology. 17 (6), 816-826 (2015).
  13. Boulanger, C. M., Loyer, X., Rautou, P. -. E., Amabile, N. Extracellular vesicles in coronary artery disease. Nature Reviews Cardiology. 14, 259 (2017).
  14. Zhu, X., et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. Journal of Extracellular Vesicles. 6 (1), 1324730 (2017).
  15. Vader, P., Mol, E. A., Pasterkamp, G., Schiffelers, R. M. Extracellular vesicles for drug delivery. Advanced Drug Delivery Reviews. 106, 148-156 (2016).
  16. Ingato, D., Lee, J. U., Sim, S. J., Kwon, Y. J. Good things come in small packages: Overcoming challenges to harness extracellular vesicles for therapeutic delivery. Journal of Controlled Release. 241, 174-185 (2016).
  17. Gimona, M., Pachler, K., Laner-Plamberger, S., Schallmoser, K., Rohde, E. Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use. International Journal of Molecular Sciences. 18 (6), 1190 (2017).
  18. Jeyaram, A., Jay, S. M. Preservation and Storage Stability of Extracellular Vesicles for Therapeutic Applications. The AAPS Journal. 20 (1), 1 (2017).
  19. Lőrincz, &. #. 1. 9. 3. ;. M., et al. Effect of storage on physical and functional properties of extracellular vesicles derived from neutrophilic granulocytes. Journal of Extracellular Vesicles. 3, 25465 (2014).
  20. Kreke, M., Smith, R., Hanscome, P., Peck, K., Ibrahim, A. Processes for producing stable exosome formulations. US patent. , (2016).
  21. Frank, J., et al. Extracellular vesicles protect glucuronidase model enzymes during freeze-drying. Scientific Reports. 8 (1), 12377 (2018).
  22. Charoenviriyakul, C., Takahashi, Y., Nishikawa, M., Takakura, Y. Preservation of exosomes at room temperature using lyophilization. International Journal of Pharmaceutics. 553 (1), 1-7 (2018).
  23. Kusuma, G. D., et al. To Protect and to Preserve: Novel Preservation Strategies for Extracellular Vesicles. Frontiers in Pharmacology. 9 (1199), (2018).
  24. Haney, M. J., et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. Journal of Controlled Release. 207, 18-30 (2015).
  25. Fuhrmann, G., Serio, A., Mazo, M., Nair, R., Stevens, M. M. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. Journal of Controlled Release. 205, 35-44 (2015).
  26. Théry, C., et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles. 7 (1), 1535750 (2018).
  27. Gardiner, C., Ferreira, Y. J., Dragovic, R. A., Redman, C. W. G., Sargent, I. L. Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. Journal of Extracellular Vesicles. 2 (1), 19671 (2013).
  28. Vestad, B., et al. Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. Journal of Extracellular Vesicles. 6 (1), 1344087 (2017).
  29. Bosch, S., et al. Trehalose prevents aggregation of exosomes and cryodamage. Scientific Reports. 6, 36162 (2016).
  30. Bhattacharjee, S. DLS and zeta potential - What they are and what they are not. Journal of Controlled Release. 235, 337-351 (2016).
  31. Van Deun, J., et al. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. Journal of Extracellular Vesicles. 3 (1), 24858 (2014).
  32. Taylor, D. D., Shah, S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods. 87, 3-10 (2015).
  33. Patel, D. B., et al. Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell-derived extracellular vesicles. Bioengineering & Translational Medicine. 2 (2), 170-179 (2017).
  34. Gardiner, C., et al. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. Journal of Extracellular Vesicles. 5 (1), 32945 (2016).
  35. Zhang, H., et al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nature Cell Biology. 20 (3), 332-343 (2018).
  36. Linares, R., Tan, S., Gounou, C., Arraud, N., Brisson, A. R. High-speed centrifugation induces aggregation of extracellular vesicles. Journal of Extracellular Vesicles. 4 (1), 29509 (2015).
  37. Lobb, R. J., et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. Journal of Extracellular Vesicles. 4, 27031 (2015).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Extracellular VesiclesStorage StabilityTherapeutic UseGlucuronidaseAsymmetric Flow Field Flow FractionationAF4Size Exclusion ChromatographyCell CultureSupernatantUltracentrifugationPurificationCell DebrisResuspensionSaponinEnzyme Encapsulation

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved